Food for Thought: Should the FDA, EMA, NCI, NHLBI, ICOS, ACC, AHA, mandate Cardio-Oncologists on Cancer Clinical Trials with Cardiotoxic Drugs?| Trastuzumab Cardiotoxicity in DESTINY-Breast04 Trial
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2203690#.YsoGdaAS_fY.twitter DESTINY-Changing Results for Advanced Breast Cancer | NEJM https://www.nejm.org/doi/full/10.1056/NEJMe2206661#.YsoGjty1ahE.twitter Early Detection and Monitoring of Vulnerable Myocardium in Patients Receiving Chemother